OCX Insider Trading
Insider Ownership Percentage: 1.58%
Insider Buying (Last 12 Months): $13,851,500.79
Insider Selling (Last 12 Months): $0.00
OncoCyte Share Price & Price History
Current Price: $2.85
Price Change: ▼ Price Decrease of -0.15 (-5.00%)
As of 04/2/2025 03:50 PM ET
OncoCyte Insider Trading History
OncoCyte Institutional Trading History
Data available starting January 2016
OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test. It also provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. (Bio-Rad) to collaborate in the development and the commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California.
Read More on OncoCyte
Volume
25,584 shs
Average Volume
65,296 shs
Market Capitalization
$81.51 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.79
Who are the company insiders with the largest holdings of OncoCyte?
OncoCyte's top insider investors include:
- Broadwood Partners, LP (Major Shareholder)
- Patrick W Smith (Major Shareholder)
- Pura Vida Investments, Llc (Major Shareholder)
- Andrea S James (CFO)
- Andrew Arno (Director)
- Alfred D Kingsley (Director)
- Josh Riggs (CEO)
Learn More about top insider investors at OncoCyte.